Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | LOX | P28300 | 1/20 | 0.59 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | MGMT | P16455 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24668667 | 0.84 | RECQL (0.55) | RECQLLOXLOXL3LOXL2GSK3A | |
| SCHEMBL23152494 | 0.84 | RECQL (0.66) | RECQLLOXLOXL3LOXL2GSK3A | |
| SCHEMBL4074777 | 0.82 | RECQL (0.53) | RECQLLOXLOXL3LOXL2GSK3A | |
| SCHEMBL27902689 | 0.81 | RECQL (0.52) | RECQLLOXLOXL3LOXL2TDP1 | |
| SCHEMBL27878725 | 0.81 | RECQL (0.52) | RECQLLOXLOXL3LOXL2TDP1 | |
| Hydrochloric Acid SCHEMBL28861654 | 0.81 | LOX (0.61) | RECQLLOXLOXL3LOXL2GSK3A | |
| SCHEMBL27672336 | 0.81 | RECQL (0.52) | RECQLLOXLOXL3LOXL2TDP1 | |
| SCHEMBL1503624 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL28231152 | 0.80 | LOX (0.59) | RECQLLOXLOXL3LOXL2GSK3A | |
| Hydrochloric Acid SCHEMBL28232181 | 0.80 | LOX (0.59) | RECQLLOXLOXL3LOXL2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362336-B1 | ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2002-03-26 | — | — | US | disclosed |
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | disclosed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| EP-0873319-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032208-A1 | Chemical compounds | FLT1, CNKSR1, KDR | RECQL 1574/4885LOX 1018/4885LOXL3 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.